Clinical trials: Mi Q Wave
Ischemia, Cardiac Death
A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions
E.V.O.L.U.T.I.O.N.: A Randomized Study to Evaluate Safety and Efficacy of the Excel Sirolimus Eluting Stent with a Biodegradable Polymer Versus Sirolimus Eluting Stent with a Non-Biodegradable Polymer in the Treatment of Patients…
- Conditions
- Ischemia, Cardiac Death, Myocardial Infarction
- Trial name
- EVOLUTION (NCT00825773)
- Testing
- Percutaneous Transluminal Coronary Angioplasty
- Where
- China
- Volunteers
- 1,944 people
- Sponsor
- JW Medical Systems Ltd
Mi Q Wave, Coronary Artery Disease
New Time Clock for ST-elevation MI Based on Biochemical Myocardial Infarction Onset Time
ST segment elevation myocardial infarction (STEMI) is one of the leading causes of death across the world and immediate treatment with either thrombolytics or percutaneous coronary intervention (PCI) results in lower mortality.
- Trial name
- BIT-STEMI (NCT04389814)
- Testing
- Biochemical markers
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Tabba Heart Institute
Mi Q Wave
Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome
This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome
- Trial name
- NCT06053983
- Testing
- Turbox CRP kit, rosuvastatin 20 mg,, atorvastatin 40 mg
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Rawalpindi Medical College
ST-elevation Myocardial Infarction, Acute Myocardial Infarction
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary…
- Trial name
- NCT01991366
- Where
- United States
- Sponsor
- Medstar Health Research Institute